Klin Farmakol Farm. 2005;19(2):116-120

Pharmacogenomics and nutrigenomics: complex gene-environment interactions

Ondřej Šeda1,2, Lucie Šedová1
1 Ústav biologie a lékařské genetiky 1. LF UK a VFN, Praha
2 Oddělení metabolismu diabetu, Centrum experimentální medicíny, IKEM Praha

Pharmacogenetics is an interdisciplinary field dealing with the relationships between the genetic disposition of an individual and the effects of the drugs administered at the level of particular gene polymorphisms. Since 1950s pharmacogenetics has evolved from single observations and indirect indices to highly parallel, high-throughput analyses of genetic polymorphisms affecting the action of the drugs administered. Only recently have we witnessed the advent of pharmacogenomic methods that allow to assess the effect of the drug administered on the global expression of the genetic information at levels of transcriptome, proteome and metabolome. Concurrently, the fields of nutrigenetics and nutrigenomics evolve based on the notion that common diet contains a substantial number of biologically active compounds. Their effects on the onset, course and therapy of several complex diseases are, again, partly dependent on the genetic make-up of an individual. The common goal of pharmacogenomics and nutrigenomics is personalized medicine with a possibility to ascertain the adequate type and dose of a drug together with an appropriate dietary regimen for an individual based on predictive genetic testing.

Keywords: Keywords: pharmacogenetics, pharmacogenomics, nutrigenetics.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šeda O, Šedová L. Pharmacogenomics and nutrigenomics: complex gene-environment interactions. Klin Farmakol Farm. 2005;19(2):116-120.
Download citation

References

  1. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004; 306: 640-643. Go to original source... Go to PubMed...
  2. Carson PE, Flanagan CL, Ickes CE, Alving AS. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956; 124: 484-485. Go to original source... Go to PubMed...
  3. Lehmann H, Ryan E. The familial incidence of low pseudocholinesterase level. Lancet 1956; 271: 124. Go to original source... Go to PubMed...
  4. Bőnicke R, Reif W. Enzymatische Inaktivierung von Isonicotinsäure hydrazide im menschlichen und tierischen Organismus. Arch Exp Pathol Pharmakol 1953; 220: 321-333. Go to original source...
  5. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation in man. Proc Natl Acad Sci USA 1991; 88: 5237-5241. Go to original source... Go to PubMed...
  6. Vogel F. Moderne Probleme der Humangenetik. Ergebn. Inn. Med. Kinderheilkd. 1959; 12: 52-125. Go to original source...
  7. Marshall A. Genset-Abbott deal heralds pharmacogenomics era. Nat Biotechnol 1997; 15: 829-830. Go to original source... Go to PubMed...
  8. Deloukas P, Bentley D. The HapMap project and its application to genetic studies of drug response. Pharmacogenom J 2004; 4: 88-90. Go to original source... Go to PubMed...
  9. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25: 193-200. Go to original source... Go to PubMed...
  10. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-652.
  11. Marx V. Pharmacogenomics shapes pediatrics' future. Genomics and Proteomics 2004; 4: 12-18.
  12. Nebert WN, Vesell, ES. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol 2004; 500: 267-280. Go to original source... Go to PubMed...
  13. Chang JT, Altman RB. Extracting and characterizing gene-drug relationships from the literature. Pharmacogenetics 2004; 14: 577-586. Go to original source... Go to PubMed...
  14. Hatina J, Sykes B. Lékařská genetika. Academia Praha 1999: 226-268.
  15. Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet 2004; 20: 640-647. Go to original source... Go to PubMed...
  16. Rat Genome Sequencing Project Consortium. Genome sequence of the Brown Norway rat yields insights into mammalian evolution Nature 2004; 428: 493-521. Go to original source... Go to PubMed...
  17. Křen V. Genetics of the polydactyly-luxate syndrome in the Norway rat, Rattus norvegicus. Acta Univ Carrol Med Praha (Monogr.) 1975; 68: 1-103.
  18. Bílá V, Křen V. Use of the polydactyly-luxation syndrome in rats for studying the interaction of the genome with teratogenic factors Sb 1988; Lek 90 (2-3), 90-96.
  19. Bílá V, Křen V. Evidence for teratogenicity of thalidomide using congenic and recombinant inbred rat strains. Folia Biol (Praha) 1994; 40 (4): 161-171. Go to PubMed...
  20. Bílá V, Křen V. The teratogenic action of retinoic acid in rat congenic and recombinant inbred strains. Folia Biol. (Praha) 1996; 42, 167-173. Go to PubMed...
  21. Bílá V, Křen V, Liška F. The influence of retinoic acid teratogenicity on the interaction of retinoic acid with Lx mutation of the rat. Folia Biol (Praha) 2000; 46: 260-268.
  22. Vrána A, Kazdová L, Dobešová Z, et al. Triglyceridemia, glucoregulation, and blood pressure in various rat strains Effects of dietary carbohydrates. Ann NY Acad Sci 1993; 683: 57-68. Go to original source... Go to PubMed...
  23. Šedová L, Kazdová L, Šeda O, Křenová D, Křen V. Rat inbred PD/Cub strain as a model of dyslipidemia and insulin resistance. Folia Biol (Praha) 2000; 46: 99-106. Go to PubMed...
  24. Šedová L, Šeda O, Křenová D, Křen V, Kazdová L. Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. Int J Obes Relat Metab Disord 2004; 28: 719-725. Go to original source... Go to PubMed...
  25. Šeda O, Kazdová L, Křenová D, Křen V. Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in genetic model of metabolic syndrome X. Folia Biol (Praha) 2002; 48: 237-241. Go to PubMed...
  26. Šeda O, Šedová L. PPARs: molecular targets in the pharmacogenomics era. Prague Medical Report 2004; 205: 223-236.
  27. Qi N, Kazdová L, Zídek V, et al. Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone. J Biol Chem 2002; 277: 48501-48507. Go to original source... Go to PubMed...
  28. Šeda O, Kazdová L, Křenová D, Křen V. Rosiglitazone fails to improve hypertriglyceridemia and glucose tolerance in CD36-deficient BN.SHR4 congenic rat strain. Physiol Genomics 2003; 12: 73-78. Go to original source... Go to PubMed...
  29. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004; 5: 645-656. Go to original source... Go to PubMed...
  30. Danoff TM, Campbell DA, McCarthy, et al. Pharmacogenomics J 2004; 4: 49-53. Go to original source... Go to PubMed...
  31. Šedová L, Šeda O. Nutriční genomika. Čas Lék Česk 2004; 143: 676-678. Go to PubMed...
  32. Kaput J, Rodriguez RL. Nutritional genomics: the next frontier in the postgenomic era. Physiol Genomics 2004; 16: 166-177. Go to original source... Go to PubMed...
  33. Müller M, Kersten S. Nutrigenomics: goals and strategies. Nat Rev Genet 2004; 4: 315-322. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.